

ONCE-WEEKLY

wegovy[®]

semaglutide injection **2.4 mg**

you're invited.

Join us for an upcoming event.

Obesity and CV Risk: Unpacking Clinical Trial & Real-World Findings for Wegovy[®]

Presenter: **MARIA WALLS, Nurse Practitioner**



Thursday, November 20, 2025
06:00 PM - 07:00 PM
America/Chicago



Celebrations Downtown



Host:
KEVIN HAYES



19 South Spanish Street

Cape Girardeau
Missouri
63703

To RSVP or if you have questions about this program, please call **KEVIN HAYES** at **+1 573-450-2029** or email khye@novonordisk.com

Indications and Usage

Wegovy[®] (semaglutide) injection 2.4 mg is indicated in combination with a reduced calorie diet and increased physical activity:

- to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight
- to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity and adults with overweight in the presence of at least one weight-related comorbidity

Limitations of Use: Wegovy[®] contains semaglutide. Coadministration with other semaglutide-containing products or with any GLP-1 receptor agonist is not recommended

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

- In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy[®] causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined
- Wegovy[®] is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Wegovy[®] and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Wegovy[®]

Contraindications

- Wegovy[®] is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy[®]. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with Wegovy[®]

Warnings and Precautions

- **Risk of Thyroid C-Cell Tumors:** Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging
- **Acute Pancreatitis:** Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including Wegovy[®]. Observe patients carefully for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue Wegovy[®] and initiate appropriate management

Please see additional Important Safety Information on the following page.
Please see accompanying Prescribing Information, including Boxed Warning.